Abstract
The commented judgment concerns the admissibility of repackaging medicinal products in parallel trade. It was issued in connection with new EU regulations aimed at counteracting the counterfeiting of such products. The Court examined how the regulations in question affect the scope of rights enjoyed by the owners of trademarks affixed to products, as well as the rights of entrepreneurs engaged in parallel trade.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
